Financial Review: TherapeuticsMD (NASDAQ:TXMD) versus Tilray Brands (NASDAQ:TLRY)

TherapeuticsMD (NASDAQ:TXMD) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings for TherapeuticsMD and Tilray Brands, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
Tilray Brands	2	2	3	1	2.38

Tilray Brands has a consensus target price of $5.90, suggesting a potential upside of 66.67%. Given Tilray Brands’ stronger consensus rating and higher probable upside, analysts plainly believe Tilray Brands is more favorable than TherapeuticsMD.

Profitability

This table compares TherapeuticsMD and Tilray Brands’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Tilray Brands	-16.91%	-10.47%	-7.52%

Volatility and Risk

TherapeuticsMD has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.

Earnings & Valuation

This table compares TherapeuticsMD and Tilray Brands”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02 million	7.89	-$570,000.00	$0.02	103.00
Tilray Brands	$915.45 million	0.53	-$121.40 million	($1.08)	-3.28

TherapeuticsMD has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 9.3% of Tilray Brands shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 1.6% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

TherapeuticsMD beats Tilray Brands on 9 of the 15 factors compared between the two stocks.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.